Loading...
•
Dec 31, 2022
OPKO Health Q4 2022 Earnings Report
Reported business highlights and financial results for Q4 2022.
Key Takeaways
OPKO Health's Q4 2022 revenue decreased compared to the previous year, primarily due to lower COVID-19 testing volume in the diagnostics segment. The company reported a net loss, including a non-cash expense related to the fair value of its GeneDx Holdings investment.
Pfizer is selling NGENLA® in 15 countries and expects to launch in all priority ex-U.S. markets by year-end.
BioReference Health is advancing its cost-cutting initiatives to address the decline in COVID-19 testing volume.
Pharmaceuticals revenue increased to $37.9 million, driven by international operating companies and RAYALDEE sales.
Diagnostics revenue decreased to $139.4 million due to lower COVID-19 testing volume.
Forward Guidance
OPKO's senior management will provide a business update, discuss fourth quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. Eastern time.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...